Our research

Research at the Institute of Pathology deals with the development, diagnosis and treatment of diseases. Immune pathologies, inflammatory diseases and tumor biology are the current research interests. Ex vivo studies of human tissue samples and the use of experimental in vitro and in vivo model systems are used to answer our research questions.

News

1st Faculty Prize for Dissertation

Dr. med. Melina Helbling, under the supervision of Prof. I. Zlobec, has received the 1. Prize from the Faculty of Medicine for her medical dissertation entitled “TWIST 1 and TWIST2 promoter methylation influences the EMT-like tumor budding phenotype in colorectal cancer”.

Young Investigator Communication Workshop Award, WCLC 2016

Manuel Keller received the “Young Investigator Communication Workshop Award” at the 17th IASLC World Conference on Lung Cancer, 2016, Vienna, Austria, December 4-7th. He presented his MD dissertation work: “High PD-L1 expression is associated with worse prognosis in primary resected squamous cell carcinomas of the lung”. Congratulations!

Travel Grant, ELCC 2016 European Lung Cancer Conference

Sabina Berezowska, 13.-16.04.2016, Geneva; Autophagy in early stage NSCLC – prognostic significance of the autophagy markers p62 and LC3B. We are interested in investigating autophagy in non-small cell lung cancer. In this project, we assessed the prognostic role of autophagy in primary resected early-stage lung cancer.

Congratulation to Lena Sokol, PhD

Lena Sokol received the 2016 AACR-Pezoller Foundation Scholar-In-Training Award
for her poster entitled “A signature of rejection in colorectal cancer: immune markers
and their epigenetic regulation”.

2015 Stowell-Orbison Award, United Stated and Canadian Academy of Pathology (USCAP) Boston

Viktor H Koelzer, A Twist to the Tale: Effect of TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma on the tumor budding phenotype in colorectal cancer. The project investigates the interaction between tumor cells and stromal cells in colorectal cancer with molecular methods. The epigenetic regulation of TWIST1 and TWIST2 was demonstrated.

2015 Travel Grant, United European Gastroenterology Week (UEGW)

Inti Zlobec, VE1 (BRAF V600E) immunohistochemistry in colorectal cancer: assessment of antibody performance, histopathology, prognosis and heterogeneity in three colorectal cancer cohorts. The aim of the study was to determine the sensitivity and specificity of VE1 for BRAF mutation and to investigate the heterogeneity of expression and prognostic effect in colorectal cancer.

2015 Tiniakos-Award for best contribution in GI-Pathology, 27th European Congress of Pathology

Eva Diamantis-Karamitopoulou, Indications for a strategic role of the stromal cells in the tumour progression of pancreatic cancer. Unsere Untersuchungen zeigen dass die Stromazellen in der Umgebung der Tumorbuds im Bereich der Invasionsfront des Pankreaskarzinoms regulieren das weitere Tumorwachstum durch genetische und epigenetische Veränderungen inklusiv Expression von microRNAs.

Travel grant award, Annual Meeting, American Association for Cancer Research

Aladin Haimovici, April 18-22, Philadelphia: PU.1 inhibition confers resistance to TRAIL- and anthracycline-mediated apoptosis through NF-κB activation and TRAIL receptor downregulation in acute myeloid leukemia cells

Virchows Archiv prize for the best paper of 2014

Tilman Rau, Defined morphological criteria allow reliable diagnosis of colorectal serrated polyps and predict polyp genetics

Vorherige

More News